The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

Panelists discuss how emerging therapies—including TKIs, sustained-release implants, and gene therapy—may reduce treatment ...

Advancing investigational pre-clinical research of APL-9099 3, a potential one-time neonatal Fc receptor (FcRn) treatment ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in ...

Nanoscope has received a new patent ( US Patent No. 12459977) from the US Patent and Trademark Office (USPTO) for the company ...

Aim for a balanced diet with a variety of foods in order to get enough vitamin E and vitamin K. While sun protection is good, ...

Multi-asset pipeline with significant targeted data readouts and milestones -- Two lead ophthalmic gene therapy programs in clinical trials ...

Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...

Apellis Pharmaceuticals (NASDAQ:APLS) used its presentation at the 44th Annual JPMorgan Healthcare Conference to outline its ...

A woman who lost her vision due to a rare condition before having her sight restored with injections that pumped up her eye has described the treatment as “phenomenal”.

REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases. "2026 is set to be a transformative year ...

Over the past decade, most ophthalmologists have become familiar with in-office cataract surgery, and more than 130 practices ...